Spotlight on dasatinib in chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia.
McCormack PL, Keam SJ.
BioDrugs · journal article · DOI 10.2165/11207640-000000000-00000 PUBLICATION REGISTRY
Go to research.
Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.
Publikationer som ChEBI hänvisar till för dasatinib monohydrate. Visa hela publikationsregistret
A publication hit is not a conclusion. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.
Publications in the selection
4 hitsDasatinib: an anti-tumour agent via Src inhibition.
Gnoni A, Marech I, Silvestris N, Vacca A, Lorusso V.
Curr Drug Targets · research support, non-u.s. gov't; review; journal article · DOI 10.2174/138945011794751591Pharmacological properties and clinical efficacy of dasatinib hydrate (Sprycel), an anticancer drug for chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia.
Fujii Y, Amano M, Seriu T.
Nihon Yakurigaku Zasshi · review; journal article · DOI 10.1254/fpj.134.159Sprycel for chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia resistant to or intolerant of imatinib mesylate.
Brave M, Goodman V, Kaminskas E, Farrell A, Timmer W, Pope S, Harapanhalli R, Saber H, Morse D, Bullock J, Men A, Noory C, Ramchandani R, Kenna L, Booth B, Gobburu J, Jiang X, Sridhara R, Justice R, Pazdur R.
Clin Cancer Res · journal article · DOI 10.1158/1078-0432.ccr-07-4175